OBJECTIVE: To analyze the clinicopathologic features, recurrence and survival rates, reproductive history, and treatment of patients with mucinous borderline ovarian tumors (mBOTs). MATERIAL AND METHODS: Patients with a diagnosis of mBOT were evaluated retrospectively. Patients with borderline ovarian tumors other than mucinous type and concomitant invasive cancer were excluded. RESULTS: A total of 75 patients were identified. Median age was 38 years. The most common symptom was pain (42.7%). Median CA-125 level was 23.5 IU/mL (range, 1-809 IU/mL). Median tumor size was 200 mm (range, 40-400 mm), and 6.7% of mBOTs were bilateral. Thirty-six (48%) patients underwent staging surgery. Two patients (5.9%) had nodal involvement. One patient received platinum-based adjuvant chemotherapy. One (1.3%) patient had recurrence. None of the patients died because of the ovarian tumor. A total of 43 patients had conservative surgery. CONCLUSION: Prognosis of mBOTs is excellent, and fertility-sparing surgery should be considered in the reproductive age group. Furthermore, the necessity of staging surgery is controversial.
OBJECTIVE: To analyze the clinicopathologic features, recurrence and survival rates, reproductive history, and treatment of patients with mucinous borderline ovarian tumors (mBOTs). MATERIAL AND METHODS:Patients with a diagnosis of mBOT were evaluated retrospectively. Patients with borderline ovarian tumors other than mucinous type and concomitant invasive cancer were excluded. RESULTS: A total of 75 patients were identified. Median age was 38 years. The most common symptom was pain (42.7%). Median CA-125 level was 23.5 IU/mL (range, 1-809 IU/mL). Median tumor size was 200 mm (range, 40-400 mm), and 6.7% of mBOTs were bilateral. Thirty-six (48%) patients underwent staging surgery. Two patients (5.9%) had nodal involvement. One patient received platinum-based adjuvant chemotherapy. One (1.3%) patient had recurrence. None of the patients died because of the ovarian tumor. A total of 43 patients had conservative surgery. CONCLUSION: Prognosis of mBOTs is excellent, and fertility-sparing surgery should be considered in the reproductive age group. Furthermore, the necessity of staging surgery is controversial.
Authors: F Trillsch; S Mahner; L Woelber; E Vettorazzi; A Reuss; N Ewald-Riegler; N de Gregorio; C Fotopoulou; B Schmalfeldt; A Burges; F Hilpert; T Fehm; W Meier; P Hillemanns; L Hanker; A Hasenburg; H G Strauss; M Hellriegel; P Wimberger; K Baumann; M D Keyver-Paik; U Canzler; K Wollschlaeger; D Forner; J Pfisterer; W Schroeder; K Muenstedt; B Richter; F Kommoss; S Hauptmann; A du Bois Journal: Ann Oncol Date: 2014-03-11 Impact factor: 32.976
Authors: William E Winter; Paul R Kucera; William Rodgers; John W McBroom; Cara Olsen; G Larry Maxwell Journal: Obstet Gynecol Date: 2002-10 Impact factor: 7.661
Authors: M Kleppe; J Bruls; T Van Gorp; L Massuger; B F M Slangen; K K Van de Vijver; A J Kruse; R F P M Kruitwagen Journal: Gynecol Oncol Date: 2014-02-16 Impact factor: 5.482
Authors: Cyllene R Morris; Lihua Liu; Anne O Rodriguez; Rosemary D Cress; Kurt Snipes Journal: Cancer Causes Control Date: 2013-01-13 Impact factor: 2.506
Authors: F Trillsch; S Mahner; E Vettorazzi; L Woelber; A Reuss; K Baumann; M-D Keyver-Paik; U Canzler; K Wollschlaeger; D Forner; J Pfisterer; W Schroeder; K Muenstedt; B Richter; C Fotopoulou; B Schmalfeldt; A Burges; N Ewald-Riegler; N de Gregorio; F Hilpert; T Fehm; W Meier; P Hillemanns; L Hanker; A Hasenburg; H-G Strauss; M Hellriegel; P Wimberger; S Kommoss; F Kommoss; S Hauptmann; A du Bois Journal: Br J Cancer Date: 2015-01-06 Impact factor: 7.640